SBRT found safe for medically inoperable patients with NSCLC

BOSTON, MA — Stereotactic body radiotherapy (SBRT) has been increasingly utilized for medically inoperable early stage non-small-cell lung cancer with patients with centrally located tumors receiving a lower radiation dose that what is prescribed for patients with peripherally located tumors due to normal tissue toxicity concerns. NRG-RTOG 0813: Seamless Phase I/II Study of Stereotactic Lung Radiotherapy (SBRT) for Early Stage, Centrally Located Non-Small Cell Lung Cancer (NSCLC) in Medically Inoperable Patients tested the safety of using SBRT at different dose levels for patients with centrally located NSCLC. NRG-RTOG 0813 tested SBRT on 110 patients with medically inoperable, centrally located NSCLC and found that higher does could be delivered with acceptable toxicity and produce outcomes similar to patients with peripheral disease. The primarily elderly patients were accrued onto a dose-escalating five fraction SBRT schedule ranging from 10-12 Gy/fraction (fr) delivered over one and a half to two weeks. The phase I results of this trial were presented at the 2015 American Society of Radiation Oncology (ASTRO) Annual Meeting and the phase II efficacy results were presented at the 2016 ASTRO Annual Meeting in Boston, Massachusetts, on date September 25, 2016.

"Data from phase I of the trial indicated a relatively low rate of serious toxicity on the highest dose level we planned to test, 12 Gy per fraction for five fractions; the seamless study design allowed for ongoing phase II accrual at the dose closest to maximum tolerated dose"," says Andrea Bezjak, MD, of the Department of Radiation Oncology at the Princess Margaret Cancer Center in Toronto and the primary investigator of NRG-RTOG 0813. "We were pleased to see that the higher dose levels were found to be both safe and effective as compared to data from comparable SBRT trial results."

The phase two efficacy results are based on the patients treated at the two higher dose levels : the 33 patients that were treated with 12Gy/fr (total dose 60Gy in 5 fr) and the 38 patients treated on the preceding dose level of 11.5 Gy/fr. (total dose 57.5 Gy in 5 fr)

The median follow up was 33 months for the 11.Gy/fr cohort and 29.8 months for the 12Gy/fr cohort. Late grade three or higher toxicities attributed to SBRT were two grade five toxicities for the 11.5Gy/fr cohort and in the 12Gy/fr cohort, three grade three toxicities. Two-year local control in the 11.5 Gy/fr cohort was 89.4% and in the 12 Gy/fr cohort was 87.7%. Two-year progression-free survival was 52.2% and 54.5% respectively, and two year overall survival was 70.2% and 72.7% respectively. In summary, the toxicity in the 71 patients treated at the two highest dose levels in this trial was acceptable and the local control and outcomes data comparable to SBRT results in peripherally located early stage NSCLC.


NRG-RTOG 0813 was funded by grants from the National Cancer Institute.

NRG Oncology conducts practice-changing, multi-institutional clinical and translational research to improve the lives of patients with cancer. Founded in 2012, NRG Oncology is a Pennsylvania-based nonprofit corporation that integrates the research of the National Adjuvant Breast and Bowel Project, the Radiation Therapy Oncology Group, and the Gynecologic Oncology Group. The research organization seeks to carry out clinical trials with emphases on gender-specific malignancies, including gynecologic, breast, and prostate cancers, and on localized or locally advanced cancers of all types. NRG Oncology's extensive research organization comprises multidisciplinary investigators, including medical oncologists, radiation oncologists, surgeons, physicists, pathologists, and statisticians, and encompasses more than 1300 research sites located world-wide with predominance in the United States and Canada. NRG Oncology is supported primarily through grants from the National Cancer Institute (NCI) and is one of five research groups in the NCI's National Clinical Trials Network.

Media Contact

Angela LaPenta
[email protected]